Übersetzung für "Insulinoma" in Deutsch

Insulinoma is a rare disease that primarily violates glucose metabolism.

Suspensions of the peptide aggregate (produced as described as above) were tested by means of a Rat Insulinoma (RIN5 mf) and a human astroglioma-cell series (HTB-14) for toxicity.

If your dog has collapsed or is suffering from seizures because of an insulinoma, medical emergency treatment usually will consist of immediate administration of glucose.

The most common symptom of an insulinoma is physical collapse, or loss of consciousness (syncope).

Insulinoma is one of the most frequent hormonal diseases and one of the most diagnosed tumours in ferrets.

If your dog should collapse and a blood sample indicates low glucose, insulinoma will be highly suspected and your veterinarian will need to follow through with further tests to confirm it.

Glucose values < 4 mmol/l indicates an insulinoma (Mayer, 2012).

Endocrinopathies Insulinoma is one of the most frequent hormonal diseases and one of the most diagnosed tumours in ferrets.

Some exocrine gland tumors, such as a VIPoma, an insulinoma, a pheochromocytoma, etc. are typically not referred to as adenocarcinomas.

Diagnose is made by measuring glucose in the serum from 4-6 hours fasted animals. Glucose values < 4 mmol/l indicates an insulinoma (Mayer, 2012).

Insulinomas are malignant neoplasms — fast growing cancer cells — of the beta cells in the pancreas.

Since depreotide also binds to somatostatin receptors, caution should be exercised when administering this medicinal product to patients with insulinomas or diabetes mellitus.

However, a whole series of neuroendocrine tumors (NET), among them insulinomas and small cell bronchial carcinomas, do not express the necessary subtypes of the somatostatin receptor which are essential for SRS or radiopeptide therapy with the somatostatin analog Octreotide®.

Furthermore, no GLP-1 derivatives are known which are appropriate, either labeled or unlabeled, for use in the radiotherapy of insulinomas and small cell bronchial carcinomas.

Through these peptide derivatives of GLP-1, exendin-3 and exendin-4 as well as chimeric peptides of GLP-1, exendin-3 or exendin-4 the production of a means for scintigraphic applications is carried out which will be utilized for diagnostic and therapy of GLP-1 receptor expressing tumors, including NET (especially from insulinomas) and small cell bronchial carcinomas.

NET are, above all, gastroenteropancreatic NET, such as insulinomas, for which to date no non-invasive method with sufficient sensitivity is available or of small cell bronchial carcinomas localized in the area of the lung in which case the specific differentiation between inflammable processes and tumors or metastases is neither possible by means of a non-invasive method.

Thus, the advantage of the current invention is that peptide derivatives of GLP-1 (glucagon-like peptide-1), exendin-3 and exendin-4 as well as chimeric peptides of GLP-1, exendin-3 or exendin-4 are utilized for the production of an agent, especially for the receptor-oriented specific representation and therapy, particularly of NET, in the case at hand especially of insulinomas and small cell bronchial carcinomas.

Because insulinomas secrete excessive insulin, the blood stream becomes low in glucose (a condition referred to as hypoglycemia), which causes weakness or neurological problems.